Capital Research Global Investors Astrazeneca PLC Transaction History
Capital Research Global Investors
- $463 Billion
- Q3 2024
A detailed history of Capital Research Global Investors transactions in Astrazeneca PLC stock. As of the latest transaction made, Capital Research Global Investors holds 1,080,218 shares of AZN stock, worth $71.6 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,080,218
Previous 1,395,023
22.57%
Holding current value
$71.6 Million
Previous $109 Million
22.64%
% of portfolio
0.02%
Previous 0.02%
Shares
7 transactions
Others Institutions Holding AZN
# of Institutions
1,361Shares Held
475MCall Options Held
5.39MPut Options Held
3.75M-
Price T Rowe Associates Inc Baltimore, MD62.9MShares$4.17 Billion0.56% of portfolio
-
Primecap Management CO Pasadena, CA42MShares$2.78 Billion2.45% of portfolio
-
Wellington Management Group LLP Boston, MA37.2MShares$2.47 Billion0.52% of portfolio
-
Capital International Investors Los Angeles, CA36.8MShares$2.44 Billion0.57% of portfolio
-
Franklin Resources Inc San Mateo, CA19.1MShares$1.27 Billion0.45% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $205B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...